Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1550 (-8.76%) ($5.1550 - $5.1550) on Thu. Feb. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.66% (three month average) | RSI | 44 | Latest Price | $5.1550(-8.76%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -2.9% a day on average for past five trading days. | Weekly Trend | ADMS declines -2% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) FXI(17%) MCHI(12%) VWO(8%) TLT(7%) UNG(7%) | Factors Impacting ADMS price | ADMS will decline at least -2.33% in a week (0% probabilities). JETS(-25%) VCSH(-20%) CEMB(-18%) XLY(-15%) REMX(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.33% (StdDev 4.66%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $5.87 | 5 Day Moving Average | $5.67(-9.08%) | 10 Day Moving Average | $5.88(-12.33%) | 20 Day Moving Average | $5.87(-12.18%) | To recent high | -22.6% | To recent low | 3.1% | Market Cap | $N/A | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |